Follow The Filings

TNDM Tandem Diabetes Care Inc.

Health Care, filed as TANDEM DIABETES CARE INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 1.0%
  • $5.4M

Who owns this now

Largest portfolio weights among holders, up to 1.0% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 1.0%

Who owns TNDM

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 1.0% Hold 355,208 $5.4M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TNDM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TNDM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $4,356 sold by 1 insider under 10b5-1 plans
  1. Mark David Novara EVP & Chief Commercial Officer
    Planned sale
    $4,310 187 shares at $23.05 0.5% of stake
    Traded Mar 17 Filed Mar 18
    ↗
  2. Mark David Novara EVP & Chief Commercial Officer
    Planned sale
    $46 2 shares at $22.81 <0.1% of stake
    Traded Mar 5 Filed Mar 9
    ↗

Also filed in the last 12 months, not counted as buying or selling: 77 option exercises, 69 share withholdings for taxes, 11 stock grants, 2 gifts, and 2 other transactions.

Congress

2 members of Congress traded TNDM in the last three years: 5 buys and 1 sale. 2 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Sep 29 filed Oct 12
  2. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 3 filed Apr 7
  3. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Sep 22, 2025 filed Oct 15, 2025
  4. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Mar 19, 2025 filed Apr 10, 2025
  5. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Mar 4, 2025 filed Apr 7, 2025
  6. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Aug 5, 2024 filed Sep 11, 2024

SEC filings

Recent issuer filings from EDGAR, 6 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 3.03,5.02,5.07,9.01 Filing Doc
8-K 5.02 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 3 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.748B $0.94B $1.01B
Gross profit $367.69M $489.57M $546.01M
Gross margin * 49.2% 52.1% 53.8%
Net income -$222.61M -$96.02M -$204.71M
Net margin * -29.8% -10.2% -20.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $747.99M $724.49M $618.14M
Total non-current assets * $204.67M $243.17M $262.97M
Total assets $952.66M $967.66M $881.11M
Total current liabilities $195.26M $247.05M $242.72M
Total non-current liabilities * $443.77M $457.51M $483.22M
Total equity $313.63M $263.1M $155.17M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$31.81M $24.22M -$9.72M
Cash from investing -$85.74M -$23.48M $72.88M
Cash from financing $4.11M $8.37M -$43.37M
Net change in cash -$113.65M $10.37M $21.4M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.